MedImmune
AstraZeneca deal to delve into the secretome
December 11, 2015Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome
MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
AstraZeneca’s MedImmune joins Human Vaccines Project
October 13, 2015Research and Development Human Vaccines Project, MedImmune
MedImmune has joined the Human Vaccines Project, which aims to accelerate the research and development of vaccines and immunotherapies for …
Medimmune and Cancer Research UK launch new drug discovery lab
September 11, 2015Research and Development AstraZeneca, Cambridge, Cancer, Cancer Research UK, MedImmune, R&D, george freeman
MedImmune and the UK’s biggest cancer charity have opened a new laboratory for joint cancer research.Research at the laboratory, which …
Novavax rides high on crest of RSV vaccine wave
August 12, 2015Research and Development AbbVie, MedImmune, Novavax, RSV, vaccines
The vaccine development company Novavax has announced positive top-line data from a mid-stage clinical trial of its candidate vaccine against …
MedImmune and Inovio collaborate on cancer vaccine
August 11, 2015Manufacturing and Production, Research and Development AstraZeneca, HPV, Inovio, MedImmune, cancer vaccines, cervical cancer, oncology
MedImmune has entered into a license agreement and collaboration with Inovio, a biotechnology company developing DNA-based immunotherapies for cancer and …
MedImmune and Mirati to partner on lung cancer combo
August 6, 2015Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat
MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
AstraZeneca signs immuno-oncology deal with UK firm
April 16, 2015Research and Development, Sales and Marketing AstraZeneca, IMCgp100, MEDI4736, MedImmune, Oxford, immuno-oncology, immunocore, melanoma, tremelimumab
UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies of potential new cancer treatments. …
FDA grants AstraZeneca immune drug orphan status
April 15, 2015Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab
The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …
AstraZeneca buys biotech Definiens
November 4, 2014Research and Development, Sales and Marketing AstraZeneca, Janssen, MedImmune, Pharmacyclics, binnig, definiens
AstraZeneca has strengthened its oncology capabilities with the acquisition of Definiens, a German company that has pioneered cancer imaging and …
Working Life: MedImmune’s Dr Bing Yao
October 20, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MedImmune, Working Life, bing yao
How did you find your way into your current role? When I was pursuing my doctorate in microbiology and immunology, …
AstraZeneca deepens Cambridge ties
October 16, 2014Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, CRUK, Cambridge, MRC, MedImmune
AstraZeneca along with its biologics R&D arm MedImmune are to enter into four new collaborations with the University of Cambridge. …
MedImmune and CRUK team up on cancer
September 25, 2014Sales and Marketing AstraZeneca, CRT, CRUK, Cambridge, Cancer, MedImmune
AstraZeneca’s biologics arm MedImmune has joined forces with Cancer Research UK to establish a new research laboratory in Cambridge, UK. …
MedImmune to work with biotech Advaxis on cancer
July 22, 2014Research and Development, Sales and Marketing Advaxis, AstraZeneca, Cancer, MEDI4736, MedImmune, oncology, pd1
AZ’s MedImmune has entered into a clinical trial collaboration with US biotech firm Advaxis to help develop new cancer immunotherapies. …
Genome-driven lung cancer trial launches
June 18, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Genentech, MedImmune, Pfizer, genome, lung cancer
Amgen, Genentech, Pfizer, AstraZeneca and MedImmune – AstraZeneca’s global biologics R&D arm – have each put investigative treatments into a …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
